BR0214875A - 2-guanidino-4-heterociclil quinazolinas - Google Patents

2-guanidino-4-heterociclil quinazolinas

Info

Publication number
BR0214875A
BR0214875A BR0214875-7A BR0214875A BR0214875A BR 0214875 A BR0214875 A BR 0214875A BR 0214875 A BR0214875 A BR 0214875A BR 0214875 A BR0214875 A BR 0214875A
Authority
BR
Brazil
Prior art keywords
guanidino
quinazolines
heterocyclyl
formula
quinazolins
Prior art date
Application number
BR0214875-7A
Other languages
English (en)
Inventor
Rolf Gericke
Norbert Beier
Claudia Wilm
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0214875A publication Critical patent/BR0214875A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46—Oxygen atoms
    • C07D213/50—Ketonic radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"2-GUANIDINO-4-HETEROCICLIL QUINAZOLINAS". A invenção se refere a compostos da fórmula (I): nos quais (Y) é a fórmula (II): ou a fórmula (III): e Het, R^ 1^, R^ 2^, R^ 5^, R^ 6^, R^ 7^ e R^ 8^ São como definidos acima, e sais e solvatos dos mesmos, e ao uso dos mesmos como inibidores de NHE-3.
BR0214875-7A 2001-12-15 2002-11-21 2-guanidino-4-heterociclil quinazolinas BR0214875A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10161767A DE10161767A1 (de) 2001-12-15 2001-12-15 2-Guanidino-4-heterocyclyl-chinazoline
PCT/EP2002/013061 WO2003051866A1 (de) 2001-12-15 2002-11-21 2-guanidino-4-heterocyclyl-chinazoline

Publications (1)

Publication Number Publication Date
BR0214875A true BR0214875A (pt) 2004-12-28

Family

ID=7709413

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214875-7A BR0214875A (pt) 2001-12-15 2002-11-21 2-guanidino-4-heterociclil quinazolinas

Country Status (11)

Country Link
US (1) US20050113396A1 (pt)
EP (1) EP1453823A1 (pt)
KR (1) KR20040065233A (pt)
AR (1) AR037821A1 (pt)
AU (1) AU2002342918A1 (pt)
BR (1) BR0214875A (pt)
CA (1) CA2470030A1 (pt)
DE (1) DE10161767A1 (pt)
MX (1) MXPA04005692A (pt)
PL (1) PL370174A1 (pt)
WO (1) WO2003051866A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241775B2 (en) 2003-03-24 2007-07-10 Sanofi-Aventis Deutschland Gmbh Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines
DE10312963A1 (de) * 2003-03-24 2004-10-07 Aventis Pharma Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
MX2011001821A (es) 2008-09-02 2011-03-25 Sanofi Aventis Aminoindanos sustituidos y sus analogos, y el uso farmaceutico de los mismos.
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2384318B1 (en) 2008-12-31 2017-11-15 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US20150336892A1 (en) 2012-08-21 2015-11-26 Ardelyx, Inc Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR102287207B1 (ko) 2013-04-12 2021-08-09 알데릭스, 인코포레이티드 Nhe3-결합 화합물 및 포스페이트 수송을 저해하는 방법
ME03311B (me) 2014-07-25 2019-10-20 Taisho Pharmaceutical Co Ltd Fenil teтrahidroizokvinolinsko jedinjenje supsтituisano heteroarilom
MX2019008170A (es) 2017-01-09 2020-02-07 Ardelyx Inc Compuestos útiles para tratar transtornos del tracto gastrointestinal.
EA201991676A1 (ru) 2017-01-09 2020-01-30 Арделикс, Инк. Ингибиторы nhe-опосредованного антипорта
EA202090438A1 (ru) 2017-08-04 2020-06-15 Арделикс, Инк. Производные глицерретиновой кислоты для лечения гиперкалиемии
AU2020218255A1 (en) 2019-02-07 2021-09-09 Ardelyx, Inc. Glycyrrhetinic acid derivatives for use in treating hyperkalemia
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US395526A (en) * 1889-01-01 Tenoning-ivjachine
US396495A (en) * 1889-01-22 Ink-bottle and attachment therefor
NL131733C (pt) * 1961-06-20
NL292083A (pt) * 1962-09-18
US3950526A (en) * 1970-04-20 1976-04-13 Sumitomo Chemical Company, Limited Quinazoline derivatives in pharmaceutical compositions for treating pain and inflammation
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US3900476A (en) * 1973-05-17 1975-08-19 Upjohn Co 2(2'-pyrimidylamino)quinazolines and their preparation
US3956495A (en) * 1973-10-30 1976-05-11 Eli Lilly And Company 2,4-Diaminoquinazolines as antithrombotic agents
IL102764A0 (en) * 1991-08-16 1993-01-31 Merck & Co Inc Quinazoline derivatives,and pharmaceutical compositions containing them
DE19633966A1 (de) * 1996-08-22 1998-02-26 Hoechst Ag Phenylsubstituierte Alkenylcarbonsäure-guanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE10019062A1 (de) * 2000-04-18 2001-10-25 Merck Patent Gmbh 2-Guanidino-4-aryl-chinazoline als NHE-3 Inhibitoren
KR100383080B1 (ko) * 2000-09-05 2003-05-12 주식회사 포스코 조절된 아민기 밀도와 공간을 제공하는 분자층을 표면에포함하는 기질 및 이의 제조방법
US20030139431A1 (en) * 2001-09-24 2003-07-24 Kawakami Joel K. Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors

Also Published As

Publication number Publication date
US20050113396A1 (en) 2005-05-26
MXPA04005692A (es) 2004-12-06
KR20040065233A (ko) 2004-07-21
AU2002342918A1 (en) 2003-06-30
CA2470030A1 (en) 2003-06-26
PL370174A1 (en) 2005-05-16
EP1453823A1 (de) 2004-09-08
DE10161767A1 (de) 2003-06-26
AR037821A1 (es) 2004-12-09
WO2003051866A1 (de) 2003-06-26

Similar Documents

Publication Publication Date Title
BR0214875A (pt) 2-guanidino-4-heterociclil quinazolinas
BR0112370A (pt) Derivados de glutaramida substituìda com ciclopentila como inibidores de endopeptidase neutra
NO20035327D0 (no) Biologisk aktive metylen-blått derivater
BR0110998A (pt) Derivados de fenilglicina
ATE350036T1 (de) Tetrahydroquinolin-derivate
ATE405266T1 (de) Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa
BR0207278A (pt) Derivados de ftalazinona-piperidina como inibidores de pde4
DE69716925T2 (de) Isoxazoline derivate und ihre verwendung als antimikroben
BR0115318A (pt) Derivados de (diidro)isoquinolina como inibidores da fosfodiesterase
DE69910831D1 (de) Epothilonderivate und ihre verwendung als antitumormittel
DE60121461D1 (de) Kondensierte pyridoindolderivate
BR0209149A (pt) Ftalazinonas
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
DE60008524D1 (de) Furanonderivate als inhibitoren von cathepsin s
BR0113583A (pt) 2-guanidino-4-arilquinazolinas
ATE411287T1 (de) Neue metallproteinaseinhibitoren
BR0112521A (pt) Indolquinazolinonas
ATE258930T1 (de) Dihydrobenzifurane
DE60023025D1 (de) 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
BR0014990A (pt) Derivados de tetrahidrotiopirano ranftalazinona como inibidores de pde4
DE60112960D1 (de) Kondensierte pyridoindolderivate
BR0115996A (pt) Sulfamidotienopirimidinas
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
DE60036558D1 (de) Phthalazinon-derivate als pde 4 hemmer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]